AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.» Read More
Stocks opened flat after an unexpected drop in jobless claims and a pullback in oil prices, which earlier topped $135 a barrel. A separate report showed the largest decline in housing prices on record.
New data on Pfizer's Chantix drug to help stop smoking raises new concerns about serious side effects, especially for drivers, pilots and others operating heavy machinery, researchers said on Wednesday.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.
There's way too much stuff out of ASCO to do a comprehensive blog entry that would satisfy readers--especially small-cap biotechies. I mean, there are literally thousands of pages of research being published today by analysts on the new data.
Buy stocks with long-term bullish themes, Cramer says. That way you don't have to worry about the short-term volatility in the market.
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
A host of news out of France on Tuesday, with Alstom down more than 2 percent on reports that officials are investigating it for bribery.
Q: On Fast Money’s Trader Radar we look at the stock that was lighting up screens across Wall Street. A Brooklyn born pharmaceutical firm, this company makes Celebrex, Zoloft, and Viagra. But now investors are asking if it’s found a pot of gold in its new $300 million dollar plant in county Cork, Ireland. Who is it?
While thumbing through “Parade” magazine yesterday, the fluffy publication that you find tucked inside some Sunday newspapers, I noticed an ad for Pfizer’s stop-smoking drug Chantix. It caught my eye because the company had stopped doing what’s called “branded” advertising for the pill earlier this year because of new safety concerns...
It's the kind of artwork I'm sure they weren't happy to see at Pfizer spacer headquarters this morning. The torn company logo on the front page of the Newark Star-Ledger business section above the headline, "Signs of Wear and Tear."
On St. Patrick's Day (March 17), Bernie McGinn saw a lot of green for Ford: he told CNBC the automaker was a "buy." Since then, the troubled carmaker's shares are up 65.2 percent. Where's the head of McGinn Investment Management going now?
Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.
Earnings Season shifted into high gear, both corporate results and economic statistics were all over the proverbial map, and investors and traders found opportunities in some unlikely places.
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
Pfizer held its shareholder meeting Thursday morning at the historic Memphis hotel where the ducks march through the lobby. I haven't seen the spectacle yet, but I'm told it's quite the scene. Watch my exclusive interview with Chairman and CEO Jeff Kindler.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
Pfizer's slide continues. The stock has now fallen below $20 for the first time since 1997.